DEX-G2 Biomarker Test for Early Gastric Cancer Detection
Coming Soon to U.S. Healthcare Providers
A New Era in Blood-Based Gastric Cancer Detection
DEX-G2 is a minimally invasive, PCR-based blood test designed to support early detection of gastric cancer. The test was developed through decades of research led by Ajay Goel, Ph.D., AGAF, a globally recognized expert in gastrointestinal cancer biomarkers who now serves as senior investigator at the City of Hope Comprehensive Cancer Center. DEX-G2 analyzes a proprietary combination of cell-free and exosomal miRNA biomarkers associated with gastric tumorigenesis—offering physicians a powerful new tool to enhance early clinical decision-making in high-risk patients.
Test Performance
Sensitivity (Early Detection) 1
Specificity (Early Detection) 1
AUC (Area Under Curve): 0.96, indicating outstanding diagnostic accuracy. 1
Validated in the DESTINEX multicenter trial of nearly 1,000 patient samples (JAMA Surgery), DEX-G2 supports clinical decision-making across both primary care and specialty settings.
DEX-G2 may aid in risk stratification and early detection in the following clinical scenarios:
Potential Clinical Use Cases
At-risk patients over 40 with persistent upper GI symptoms and/or family history
Adjunctive tool to help prioritize referrals for endoscopy or imaging
Surveillance in previously treated patients with early-stage gastric cancer
Populations with elevated gastric cancer risk, including Latino, Asian, and Eastern European ancestry or regions such as South Texas
Patients with Helicobacter pylori infection or pre-neoplastic gastric changes
When the Test is Positive
A Sample Diagnostic Pathway
1
DEX-G2+ Positive Result
2
Upper endoscopy with biopsy
3
Histopathologic confirmation
4
Multidisciplinary treatment planning*
(surgery, radiation, or systemic therapy)
*Note: DEX-G2 is designed to complement—not replace—standard diagnostic and surveillance protocols. Clinical decisions remain at the discretion of the treating provider.
Ordering and Logistics for Clinicians
When available, licensed U.S. healthcare providers can order the DEX-G2 test via a secure online portal on this clinician page.
Test type – PCR-based molecular assay (LDT – Laboratory Developed Test)
Ordering - Available to licensed U.S. healthcare providers via secure online portal
Processing - Conducted by CLIA-certified, CAP-accredited partner laboratories
Results - Delivered via secure, online portal with email notification
Billing - Initially private pay; CPT application to follow
Support - Full-service customer support team with access to Chief Medical Officer and Clinical Advisor for clinical questions
Stay Informed
For updates or to request notification when the test becomes available, please sign up below for email alerts.
References:
-
https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074